GPR6

Cerevance Presents at IAPRD XXIX World Congress on Parkinson’s Disease and Related Disorders

Retrieved on: 
Donnerstag, Mai 9, 2024
Patient, CNS, Therapy, International Association, GPR6, XXIX, Central nervous system

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, will present an oral presentation at the upcoming International Association of Parkinsonism and Related Disorders (IAPRD) XXIX World Congress on Parkinson’s Disease and Related Disorders, taking place in Lisbon, Portugal from May 19-22, 2024.

Key Points: 
  • BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, will present an oral presentation at the upcoming International Association of Parkinsonism and Related Disorders (IAPRD) XXIX World Congress on Parkinson’s Disease and Related Disorders, taking place in Lisbon, Portugal from May 19-22, 2024.
  • Overview: In a Phase 2 clinical trial, CVN424, a novel, non-dopaminergic, GPR6 inverse agonist, demonstrated a significant reduction in OFF time and was safe and well tolerated with low rates of mostly mild and moderate adverse events.
  • Patients also reported enhanced motor functionality in daily activities, as assessed by the UPDRS Part II.
  • These findings enhance the confidence in CVN424's potential to address both motor and non-motor symptoms of Parkinson’s disease, consistent with observations in pre-clinical models, potentially heralding a transformative non-dopaminergic therapy.

Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline

Retrieved on: 
Donnerstag, April 25, 2024
Doctor of Philosophy, Parkinson's disease, Protein, Central nervous system disease, ALS, GV (company), MD, Research, CNS, Therapy, GPR6, Frontotemporal dementia, Patient, MPP, Central nervous system, KCNK13, MBA, Drug development, Drug discovery, Series, Pharmaceutical industry

BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced an initial closing of its Series B-1 Extension financing round that will add $47 million to the $51 million previously raised bringing the total Series B-1 raise to $98 million. The financing is led by Agent Capital, Bioluminescence Ventures, and Double Point Ventures, with participation from new investors MQB Partners and LifeRock Ventures and existing investors Gates Frontier, GV (Google Ventures), and Lightstone Ventures. In conjunction with the financing, Campbell Murray, MD, MPP, MBA, Partner at Agent Capital and Kouki Harasaki, Ph.D., MBA, Founder and Managing Partner at Bioluminescence Ventures, have joined the Cerevance Board of Directors.

Key Points: 
  • “The support from new and existing investors underscores the ongoing advancements made by Cerevance,” said Craig Thompson, chief executive officer of Cerevance.
  • “The remarkable NETSseq platform is accelerating innovation and tangible clinical benefits are emerging from Cerevance's precision approach to CNS therapies.
  • Cerevance is advancing a robust and expanding pipeline of clinical and preclinical programs, including the lead program, CVN424, a first-in-class, oral, non-dopaminergic compound acting on a novel target (GPR6).
  • The company’s earlier-stage pipeline includes multiple first-in-class opportunities in preclinical development, including programs focused on disease modification in Parkinson’s disease and Alzheimer’s disease.

Cerevance Announces Presentations at AD/PD™ 2023 International Conference

Retrieved on: 
Montag, März 20, 2023
Neuron, Human, Tremor, Central nervous system, PD, Therapy, Life, Alzheimer's disease, Cerev Del, DSM-IV codes, Brain, CNS, KCNK13, ESS, International Conference on Emerging Infectious Diseases, Patient, Epworth Sleepiness Scale, GPR6, Drug discovery, OFF, FTD, LBD, Conference, Pharmaceutical industry, Palladium

BOSTON, March 20, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present two symposium oral presentations and a poster presentation at the upcoming AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Gothenburg, Sweden, March 28 – April 1, 2023.

Key Points: 
  • Patients also reported better experiences of motor aspects of daily living as measured with the UPDRS Part II.
  • The company will also present a poster session characterizing CVN417, a novel and selective modulator of neuronal acetylcholine receptor subunit alpha-6 (nAChR⍺6).
  • Using the NETSseq platform, nAChR⍺6 expression has been shown to be selectivity enriched in PD-relevant dopaminergic neurons in humans.
  • CVN417, which can modulate striatal dopamine release in rodents, has demonstrated efficacy in a rodent model of resting tremor and therefore may have therapeutic utility in PD.

Cerevance Expands Series B Financing with Additional $51 Million 

Retrieved on: 
Montag, Februar 13, 2023
MSD, GV (company), Somnolence, ALS, Protein, Therapy, Safety, Patient, OFF, Schizophrenia, GPR6, CNS, Foresite Capital, DSM-IV codes, Antagonist, Takeda, L-DOPA, KCNK13, Central nervous system, Pharmaceutical industry, Vaccine, Cerev Del, GV, Merck

BOSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced an expansion of its Series B funding round with an additional close of $51 million, bringing the total Series B financing to $116 million. The financing will support upcoming clinical trials focused on Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), and schizophrenia.

Key Points: 
  • BOSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced an expansion of its Series B funding round with an additional close of $51 million, bringing the total Series B financing to $116 million.
  • The financing will support upcoming clinical trials focused on Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), and schizophrenia.
  • “We are thrilled to secure additional funding from world-class investors who strongly support the need for novel therapies to treat neurological diseases,” said Craig Thompson, chief executive officer of Cerevance.
  • The additional financing announced today includes participation from Gates Frontier, Dementia Discovery Fund, Foresite Capital, GV (Google Ventures), Lightstone Ventures, Takeda Ventures, UPMC Enterprises and Dolby Family Ventures.

Cerevance to Present at the RBC Capital Markets Virtual Healthcare Private Company Conference

Retrieved on: 
Mittwoch, Dezember 7, 2022
Central nervous system, Conference, Protein, Neurodegeneration, GPR6, CNS, Patient, Amyotrophic lateral sclerosis, Pharmaceutical industry, Cerev Del

BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced that Craig Thompson, chief executive officer of Cerevance, will present at the upcoming RBC Capital Markets Virtual Healthcare Private Company Conference being held virtually December 14-15, 2022.

Key Points: 
  • BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced that Craig Thompson, chief executive officer of Cerevance, will present at the upcoming RBC Capital Markets Virtual Healthcare Private Company Conference being held virtually December 14-15, 2022.
  • Cerevance is a private pharmaceutical company whose lead therapeutic, CVN424, a first-in-class, oral, non-dopaminergic compound acting on a novel target (GPR6), demonstrated significant and clinically meaningful efficacy in a 135-patient Phase 2 study in patients with Parkinson’s disease.
  • The company uses its proprietary NETSseq technology platform to identify highly selectively novel target proteins that are either specific to certain brain circuits or are over- or under-expressed in diseased brains.
  • Partnering with over 25 brain banks and evaluating more than 12,000 human post-mortem brain tissue samples, Cerevance is advancing a robust pipeline of targeted treatments for patients with neurodegenerative diseases, including Parkinson’s disease, Amyotrophic Lateral Sclerosis and Alzheimer’s disease.

Cerevance Announces Presentation of Preclinical Data During the Cold Spring Harbor Laboratory (CSHL) Neurodegenerative Diseases - Biology and Therapeutics Conference and Publication in Neuropharmacology

Retrieved on: 
Mittwoch, November 30, 2022
Channel 1, Conference, Cold Spring Harbor Laboratory, Therapy, AD, Patient, NLRP3, Protein, Inflammation, Central nervous system, Microglia, Cold, Neuropharmacology, CNS, Amyotrophic lateral sclerosis, GPR6, Neurodegeneration, Biology, Gene expression, Tandem, CSHL, HIV disease progression rates, Pharmaceutical industry, Vaccine, Data, Cerev Del

BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced the presentation of preclinical data supporting the use of the company’s Nuclear Enriched Sort sequencing (NETSseq) technology platform to identify novel, druggable targets involved in the regulation of neuroinflammation in Alzheimer’s disease (AD). The data will be presented during the CSHL Neurodegenerative Disease - Biology and Therapeutics Conference held at the Cold Spring Harbor Laboratory from November 30 – December 2, 2022.

Key Points: 
  • The data will be presented during the CSHL Neurodegenerative Disease - Biology and Therapeutics Conference held at the Cold Spring Harbor Laboratory from November 30 December 2, 2022.
  • In addition, this data has been published in the peer-reviewed journal Neuropharmacology.
  • The article, titled, Characterisation of C101248: A novel selective THIK-1 channel inhibitor for the modulation of microglial NLRP3-inflammasome, is available on the publishers website.
  • Overall, the data demonstrate the promise of C101248 as a candidate for the treatment of AD.

Cerevance Announces Presentation of Preclinical Study Results at the Society for Neuroscience Conference

Retrieved on: 
Dienstag, November 15, 2022
Cell, Neuroinflammation, Antibody, RNA, Factor X, Patient, Society, NLRP3, FACS, Protein, Central nervous system, Microglia, GPR6, SFN, CNS, Bracewell probe, Neurodegeneration, Gene expression, Membrane protein, Neuron, Pharmaceutical industry, Vaccine, Cerev Del

BOSTON, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, announced the presentation of preclinical study results during the poster session held November 14th at the Society for Neuroscience (SFN) 2022 conference in San Diego, California.

Key Points: 
  • NETSseq is a powerful tool to identify previously unelucidated drug targets for the development of novel therapies.
  • Key highlights of the presentation include:
    Using NETSseq, tandem pore domain halothane-inhibited potassium channel 1 (THIK-1) demonstrated significantly restricted gene expression in microglia which is increased in Alzheimers diseased human brain samples.
  • Overall, the data demonstrate the promise of blocking the target THIK-1 with molecules such as C101248 for the treatment of Alzheimers disease.
  • These probes tag specific cell types in brain tissue to enable the sorting of nuclei using fluorescence-activated cell sorting (FACS).

Cerevance to Present at the Society for Neuroscience (SFN) 2022

Retrieved on: 
Montag, November 7, 2022
GLOBE, Central nervous system, Protein, CNS, Neurodegeneration, SFN, Society, GPR6, Patient, Pharmaceutical industry, Cerev Del

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced a poster presentation at the Society for Neuroscience (SFN) 2022 conference, to be held in San Diego, California and virtually on November 12-16, 2022.

Key Points: 
  • BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced a poster presentation at the Society for Neuroscience (SFN) 2022 conference, to be held in San Diego, California and virtually on November 12-16, 2022.
  • For more information and registration details, see the SFN website here .
  • The company uses its proprietary NETSseq technology platform to identify highly selective novel target proteins that are either over- or under-expressed in diseased brains.
  • Partnering with over 20 brain banks and evaluating more than 11,000 human post-mortem brain tissue samples, Cerevance is advancing a robust pipeline of targeted treatments for patients with neurodegenerative diseases, including Parkinsons disease and Alzheimers disease.

Cerevance Appoints Ottavio V. Vitolo, M.D., as Chief Medical Officer

Retrieved on: 
Montag, Oktober 3, 2022
Massachusetts General Hospital, CNS, Hospital, Drug development, GPR6, Head, Protein, Medicine, Harvard Medical School, Neuropsychiatry, Therapy, Pfizer, Alcyone and Ceyx, Patient, Central nervous system, Neurodegeneration, University, Washington University in St. Louis, GLOBE, Neurology, Pharmaceutical industry, Brigham, Cerev Del

as chief medical officer.

Key Points: 
  • as chief medical officer.
  • We are thrilled to welcome Ottavio whose expertise will help advance our broad portfolio of innovative treatments for neurodegenerative diseases, said Craig Thompson, chief executive officer of Cerevance.
  • Dr. Vitolo most recently served as chief medical officer and global head of R&D at Alcyone Therapeutics.
  • Prior to this position, Dr. Vitolo served as senior vice president, head of R&D and chief medical officer at Relmada Therapeutics Inc.

Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease

Retrieved on: 
Dienstag, August 9, 2022
MSD, CNS, GLOBE, B cell, Discovery, GPR6, Patient, Central nervous system, Therapy, Neurodegeneration, Biology, Neuroscience, Protein, Merck & Co., Pharmaceutical industry, Merck, Cerev Del

BOSTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform. Cerevance will concurrently out-license one discovery-stage program to Merck as part of the collaboration.

Key Points: 
  • Cerevance will concurrently out-license one discovery-stage program to Merck as part of the collaboration.
  • We believe we are well-positioned to identify novel targets for neurodegenerative diseases and look forward to collaborating with Merck to potentially bring forward transformative therapeutics for patients with Alzheimers disease.
  • We look forward to advancing the discovery program as well as taking advantage of the NETSseq platform to identify new targets with the team at Cerevance.
  • As a result, Cerevances platform can reveal novel therapeutic targets that can be modulated to correct neural circuitry or slow the disease process.